UniQure N.V. (QURE) Upgraded to Overweight as Huntington’s Disease Program Advances

We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. UniQure N.V. (NASDAQ:QURE) is among the best healthcare stocks.

TheFly reported on June 18 that Barclays raised its rating on QURE to Overweight from Equal Weight and increased its price target to $65 from $25. The firm viewed QURE’s planned Biologics License Application (BLA) submission for Huntington’s disease in the third quarter as a significant positive catalyst. Barclays also improved its probability assessment for the program’s success and highlighted the potential value of Huntington’s disease opportunity, estimating substantial upside for shares based on the possibility of a multibillion-dollar peak sales opportunity.

Separately, on June 19, UniQure N.V. (NASDAQ:QURE) announced preliminary six-month follow-up findings from the initial low-dose group of its ongoing Phase I/IIa study evaluating AMT-260, an investigational gene therapy for refractory mesial temporal lobe epilepsy. Data from the six participants showed that three patients experienced notable reductions in disabling seizures during months four through six, with decreases ranging from 79% to complete reduction compared with baseline. The remaining patients showed mixed seizure changes during the follow-up period. No serious adverse events linked to AMT-260 or the surgical procedure were reported, and observed side effects were mild to moderate, with headache being the most common. Enrollment continues in a higher-dose cohort.

UniQure N.V. (NASDAQ:QURE) is a biopharmaceutical company developing one-time AAV-based gene therapies for severe genetic and central nervous system diseases, aiming to deliver potentially curative treatments.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.